Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua A Roth

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
The Oncologist|March 1, 2017
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and OpportunitiesJoshua A Roth, Bernardo H L Goulart, Arliene Ravelo, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2025
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature ReviewJoshua A Roth, Victoria W Dayer, Mireia Jofre-Bonet, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Cost-effectiveness of a computerized provider order entry system in improving medication safety ambulatory careSara H Forrester, Zsolt Hepp, Joshua A Roth, et al.
JAMA Pediatrics|March 22, 2021
A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid PerspectivePatrick DeMartino, Meredith B Haag, Alyssa R Hersh, et al.
Advances in Therapy|January 30, 2022
Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast CancerJesse A Sussell, Joshua A Roth, Craig S Meyer, et al.
Bone Marrow Transplantation|June 1, 2020
Value and affordability of CAR T-cell therapy in the United StatesSalvatore Fiorenza, David S Ritchie, Scott D Ramsey, et al.
Plos One|April 8, 2015
The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesBruce Wang, Joshua A Roth, Hiep Nguyen, et al.
Plos One|July 6, 2018
A qualitative study exploring patient motivations for screening for lung cancerJoshua A Roth, Lisa Carter-Harris, Susan Brandzel, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|April 4, 2015
The Relationship of Perceived Risk and Biases in Perceived Risk to Fracture Prevention Behavior in Older WomenSalene M W Jones, Nancy M Gell, Joshua A Roth, et al.
Family Practice|January 27, 2017
A qualitative study exploring why individuals opt out of lung cancer screeningLisa Carter-Harris, Susan Brandzel, Karen J Wernli, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
The Oncologist|March 1, 2017
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and OpportunitiesJoshua A Roth, Bernardo H L Goulart, Arliene Ravelo, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2025
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature ReviewJoshua A Roth, Victoria W Dayer, Mireia Jofre-Bonet, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Cost-effectiveness of a computerized provider order entry system in improving medication safety ambulatory careSara H Forrester, Zsolt Hepp, Joshua A Roth, et al.
JAMA Pediatrics|March 22, 2021
A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid PerspectivePatrick DeMartino, Meredith B Haag, Alyssa R Hersh, et al.
Advances in Therapy|January 30, 2022
Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast CancerJesse A Sussell, Joshua A Roth, Craig S Meyer, et al.
Bone Marrow Transplantation|June 1, 2020
Value and affordability of CAR T-cell therapy in the United StatesSalvatore Fiorenza, David S Ritchie, Scott D Ramsey, et al.
Plos One|April 8, 2015
The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesBruce Wang, Joshua A Roth, Hiep Nguyen, et al.
Plos One|July 6, 2018
A qualitative study exploring patient motivations for screening for lung cancerJoshua A Roth, Lisa Carter-Harris, Susan Brandzel, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|April 4, 2015
The Relationship of Perceived Risk and Biases in Perceived Risk to Fracture Prevention Behavior in Older WomenSalene M W Jones, Nancy M Gell, Joshua A Roth, et al.
Family Practice|January 27, 2017
A qualitative study exploring why individuals opt out of lung cancer screeningLisa Carter-Harris, Susan Brandzel, Karen J Wernli, et al.
Pageof 6